Hepatocellular Carcinoma
Conditions
Keywords
apatinib, advanced hepatocellular carcinoma
Brief summary
The purpose of this study is to evaluate the efficacy and safety of apatinib in patients with advanced HCC.
Detailed description
Hepatocellular carcinoma (HCC) is the most common primary malignant tumor of the liver. It is lack of effective drugs for systemic treatment of HCC. Currently, Sorafenib is the only choice approved by FDA for advanced HCC, although it prolongs the survival for less than 3 months. The treatment of advanced HCC still has a long way to go. At present, the relevant phase II and phase III clinical studies of apatinib on advanced HCC are ongoing. Based on our important discovery of our previous clinical studies, we intends to enlarge the sample size and make further observation for the efficacy and safety of apatinib in patients with advanced HCC.
Interventions
DRUGApatinib
500mg, once a day, oral of each 28 day cycle. Number of cycle: until progression or unacceptable toxicity develops.
Sponsors
Tianjin Medical University Cancer Institute and Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Before doing any research steps, the patient's informed consent must be obtained first. 2. The diagnosis of HCC: histologic diagnosis or Alpha fetoprotein (AFP) with two kinds of imaging diagnosis. 3. Patients of Barcelona stage(BCLC) C with first-line treatment failure or non tolerance to sorafenib. 4. Ages of 18 to 75 years old. 5. Child-Pugh score between 5-7 points, patients of Child-Pugh 7 points should be without ascites. 6. Eastern Cooperative Oncology Group performance score (ECOG PS) is 0-1 point. 7. Adequate organ function meeting the following: Hemoglobin(HBG)≧9.0g/dl Neutrophil count(ANC) ≧1,500/mm3 Platelet count(PLT)≧50,000/ul Total bilirubin (TBIL)\< 2mg/dL (3mg/dL, Child-Pugh B) Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST) \< 5×ULN (upper limit of normal) ALP (alkaline phosphatase ) \< 4×ULN PT (prothrombin time) \>50% or PT-INR\<2.3, \<6 seconds or greater than that of the control 8. For patients taking warfarin, at least once a week to a close monitoring of the patients, until, according to the standard of treatment, at every time of medication, the subjects' INR measurements has been stable 9. SCr (serum creatinine) \<1.5×ULN 10. For pregnant women, the results of serum pregnancy tests must be negative within 14 days before initiation of treatment. 11. All men and women who participated in the study had to take reliable contraceptive measures within the trial and two weeks of after the trial.
Exclusion criteria
1. Patients of Child-Pugh 7 has serious uncontrolled ascites. 2. Patients with serious cardiovascular disease. 3. Patients with high blood pressure of unable to control. 4. Patients has the history of HIV (human immunodeficiency virus) infection. 5. Active clinical severe infection (\> 2, NCI-CTCAE version 3). 6. Need to drug treatment of patients with epilepsy (such as steroid or antiepileptic drugs) 7. Has a history of allogeneic organ transplantation. 8. Patients with a history of physical signs or have a bleeding. 9. Patients undergoing renal dialysis. 10. Metastatic liver cancer. 11. Patients with uncontrollable ascites. 12. Patients with encephalopathy. 13. Patients has history of gastrointestinal bleeding period of 30 days before join the study. 14. Patients with a history of esophagus varicosity burst hemorrhage, then not effective treatment or therapy to prevent recurrence of bleeding.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective Response Rate(ORR) | one year |
Secondary
| Measure | Time frame |
|---|---|
| Disease Control Rate (DCR) | one year |
| Progression free survival (PFS) | one year |
| Overall survival (OS) | one year |
| Number of participants with treatment-related adverse events as assessed by CTCAE v4.0[Quality of life] | one year |
| Incidence of Treatment-Emergent Adverse Events [Safety] | one year |
Countries
China
Contacts
Primary ContactTi Zhang, MD
Backup ContactHui-Kai Li, MD
Outcome results
None listed